Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Revenue of Lupin Limited (LUPIN.NS)
Revenue in 2023 (TTM): $2.33 B
According to Lupin Limited's latest financial reports the company's current revenue (TTM) is $2.33 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lupin Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.33 B | $1.48 B | $437.52 M | $286.67 M | $226.57 M |
| 2022 | $1.93 B | $1.12 B | $213.62 M | $84.79 M | $50.9 M |
| 2021 | $1.92 B | $1.08 B | $-51,899,380 | $-162,395,330 | $-180,837,161 |
| 2020 | $1.77 B | $1.07 B | $313.34 M | $198.4 M | $143.97 M |
| 2019 | $1.79 B | $1.09 B | $240.44 M | $89.62 M | $-31,881,183 |
| 2018 | $1.94 B | $1.19 B | $299.88 M | $179.55 M | $71.78 M |
| 2017 | $1.84 B | $1.16 B | $215.04 M | $64.71 M | $29.74 M |
| 2016 | $2.01 B | $1.35 B | $542.84 M | $419.32 M | $302.66 M |
| 2015 | $1.62 B | $1.05 B | $455.98 M | $406.28 M | $268.73 M |
| 2014 | $1.49 B | $954.38 M | $456.74 M | $404.13 M | $284.41 M |
| 2013 | $1.31 B | $827.54 M | $368.99 M | $335.11 M | $217.33 M |
| 2012 | $1.12 B | $670.26 M | $271.92 M | $227.77 M | $155.53 M |
| 2011 | $838.23 M | $530.07 M | $172.2 M | $141.55 M | $102.68 M |
| 2010 | $675.38 M | $410.53 M | $142.01 M | $117.91 M | $102.08 M |
| 2009 | $561.02 M | $327.95 M | $118.12 M | $98.9 M | $80.67 M |
| 2008 | $446.86 M | $257 M | $88.04 M | $71.72 M | $59.36 M |
| 2007 | $320.29 M | $182.56 M | $76.01 M | $63.93 M | $48.31 M |
| 2006 | $238.31 M | $128.01 M | $58.14 M | $48.22 M | $36.52 M |
| 2005 | $200.64 M | $102.9 M | $35.23 M | $26.69 M | $20.47 M |
| 2004 | $149.25 M | $73.02 M | $18.56 M | $11.24 M | $10.91 M |
| 2003 | $143.81 M | $70.15 M | $32.34 M | $22.62 M | $16.49 M |